Based on this YouTube video's total view count of 1.09K views and industry-standard rates, the estimated total earning is $1 - $2 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore The Phase III STARGLO trial: Glofit-GemOx versus R-GemOx for R/R DLBCL with 1,089 views, 7 likes, and 0 comments. Experience the impact of this video content that has captured audience attention.

In this presentation, Jeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, discusses the Phase III STARGLO trial (NCT04408638), which compared the safety and efficacy of glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) versus rituximab-GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after at least one prior line of therapy. This press briefing took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.